Application of ring-fused compound
By using CDK4/6 inhibitors, such as Palbociclib, the problem of lack of effective drug treatment for traditional chordomas is solved, and partial remission or disease stabilization effects are achieved in clinical practice, providing new drug choices for the treatment of chordomas.
CN120189510APending Publication Date: 2025-06-24PHIL RIVERS TECH LTD
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202411906029.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-01
- Filing Date
- 2024-12-23
- Publication Date
- 2025-06-24
AI Technical Summary
Technical Problem
Traditional chordoma lacks effective drug treatment methods, and existing drug treatment effects are limited.
Method used
CDK4/6 inhibitors are used as drugs for the treatment of traditional chordoma. Specific substance A includes Palbociclib and its similar compounds. They are administered orally, with a dosage of (75-500) mg/day, a dosage frequency of (1-3) times/day, and a dosage cycle of 14-42 days.
Benefits of technology
Clinical experiments show that CDK4/6 inhibitors have good therapeutic effects on traditional chordomas, can achieve partial remission or disease stability, and provide new drug treatment plans.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses an application of a ring-fused compound. The invention provides application of a substance A in preparation of a medicine for treating traditional chordoma. The substance A is a CDK4 / 6 inhibitor. Experimental data show that the CDK4 / 6 inhibitor has an obvious effect on treating traditional chordoma and is ineffective to differentiated chordoma; when the traditional chordoma is treated, experimental data prove that the symptoms of a patient are partially relieved or the disease is stable.
Need to check novelty before this filing date? Find Prior Art